

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- diagnosis of CLL/SLL and with active disease requires therapy - able to swallow and retain oral medication - at least capable of all selfcare but may unable to carry out any work activities; up and about more than 50% of waking hours - see link to clinicaltrials.gov for complete inclusion criteria

Exclusion Criteria:

- active hepatitis B virus/ hepatitis C virus - history of severe bleeding disorder - clinically significant cardiovascular disease - see link to clinicaltrials.gov for complete exclusion criteria

Conditions & Interventions

Conditions:

Cancer

Keywords:

chronic lymphocytic leukemia, CLL, SLL, small lymphocytic lymphoma

More Information

Description: The goal of this study is to evaluate nemtabrutinib compared with either ibrutinib or acalabrutinib for treatment of people with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have not received any prior therapy.

Study Contact: Kristen Nelson - knelso65@fairview.org

Principal Investigator: Puneet Cheema

Phase: PHASE3

IRB Number: MMCORC093

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfnder@umn.edu if you have questions or need assistance.